申请人:SMITHKLINE BECKMAN CORPORATION
公开号:EP0294973A1
公开(公告)日:1988-12-14
Compounds of the formula (I):
wherein X is H, F, Cl, Br, I, C₁₋₄alkyl, CN, NO₂, SO₂NH₂, COOH, OH, CHO, C₁₋₄alkoxy, CH₂OH, CH₂OC₁₋₄alkyl, CF₃, C₂F₅, C₃F₇, SO₂CH₃, SO₂CF₃, or CO₂CaH2a+1 wherein a is 1-5, or any accessible combination thereof of up to 5 substituents; R and R′ independently are H or C₁₋₄alkyl; and n is 1-5; or any pharmaceutically acceptable salt or hydrate thereof, processes for their preparation; intermediates used in their preparation; compositions containing them and their use in therapy as dopamine-β-hydroxylase inhibitors.
式 (I) 的化合物:
其中 X 是 H、F、Cl、Br、I、C₁₋₄alkyl、CN、NO₂、SO₂NH₂、COOH、OH、CHO、C₁₋₄alkoxy、CH₂OH、CH₂OC₁₋₄alkyl、CF₃、C₂F₅、C₃F₇、SO₂CH₃、SO₂CF₃,或 CO₂CaH2a+1(其中 a 为 1-5),或其中最多 5 个取代基的任何可获得的组合;R和R′独立地为H或C₁₋₄烷基;且n为1-5;或其任何药学上可接受的盐或
水合物,其制备工艺;用于制备它们的中间体;含有它们的组合物以及它们作为
多巴胺-β-羟化酶
抑制剂在治疗中的用途。